Atkin Marc, Laight David, Cummings Michael H
Department of Diabetes, Royal United Hospital, Bath, UK.
School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK.
J Diabetes Complications. 2016 May-Jun;30(4):723-7. doi: 10.1016/j.jdiacomp.2016.01.003. Epub 2016 Jan 6.
Endothelial dysfunction, vascular inflammation and oxidative stress have been integrally linked to the pathogenesis of both type 2 diabetes and cardiovascular disease. Aged Garlic Extract (AGE), a potent antioxidant, has been shown in previous studies to attenuate these novel risk factors in a non-diabetic population.
This study tested the hypothesis that AGE may improve endothelial function, oxidative stress, vascular inflammation and insulin resistance in high risk cardiovascular subjects with type 2 diabetes.
A double blind, placebo controlled crossover pilot study was performed in 26 subjects with type 2 diabetes who received 1200 mg of AGE or placebo daily for 4 weeks with a 4 week washout period. Plasma HsCRP was measured as a marker of inflammation. Plasma TAOS, blood GSH/GSSG and plasma LHP were measured as markers of oxidative stress/anti-oxidant defense. Insulin resistance was measured using the HOMA-IR method. Endothelial function was measured using change in the reflective index (RI) post-salbutamol using digital photoplethysmography and urinary albumin/creatinine ratio was measured as a biochemical surrogate. Measurements were taken at baseline and after intervention with AGE or placebo.
Of the 26 patients studied (male 17, female 9), age was 61 ± 8 years (mean ± 1 SD), HbA1c 7.2 ± 1.1%, BP 130/75 ± 15.9/9.8 mmHg, total cholesterol 4.2 ± 0.81 mmol/l, triglyceride 2.11 ± 1.51 mmol/l, and HDL cholesterol 1.04 ± 0.29 mmol/l. The majority of patients were being treated with metformin (59%), aspirin (50%) and statin (96%) therapy. 36% were treated with an ACEI. There were no changes in these therapies throughout the study. Treatment with AGE had no significant effect upon the above metabolic parameters including insulin resistance. Treatment with AGE also had no significant effect on markers of endothelial function (plethysmography), oxidative stress (TAOS, GSH/GSSG, LHP) or inflammation (HsCRP).
In this group of type 2 diabetic patients at high cardiovascular risk, 4 weeks treatment with AGE did not significantly improve endothelial function, vascular inflammation, oxidative stress or insulin resistance.
内皮功能障碍、血管炎症和氧化应激与2型糖尿病和心血管疾病的发病机制密切相关。陈年大蒜提取物(AGE)是一种有效的抗氧化剂,先前的研究表明,它可以减轻非糖尿病人群中的这些新的危险因素。
本研究检验了AGE可能改善2型糖尿病高危心血管受试者的内皮功能、氧化应激、血管炎症和胰岛素抵抗这一假设。
对26名2型糖尿病患者进行了一项双盲、安慰剂对照的交叉试点研究,这些患者每天接受1200毫克AGE或安慰剂治疗,为期4周,有4周的洗脱期。测量血浆高敏C反应蛋白(HsCRP)作为炎症标志物。测量血浆总抗氧化能力(TAOS)、血液中还原型谷胱甘肽/氧化型谷胱甘肽(GSH/GSSG)和血浆晚期氧化蛋白产物(LHP)作为氧化应激/抗氧化防御的标志物。使用稳态模型评估胰岛素抵抗指数(HOMA-IR)方法测量胰岛素抵抗。使用数字光电容积描记法测量沙丁胺醇后反射指数(RI)的变化来评估内皮功能,并测量尿白蛋白/肌酐比值作为生化替代指标。在基线以及接受AGE或安慰剂干预后进行测量。
在研究的26名患者中(男性17名,女性9名),年龄为61±8岁(平均值±1标准差),糖化血红蛋白(HbA1c)为7.2±1.1%,血压为130/75±15.9/9.8毫米汞柱,总胆固醇为4.2±0.81毫摩尔/升,甘油三酯为2.11±1.51毫摩尔/升,高密度脂蛋白胆固醇为1.04±0.29毫摩尔/升。大多数患者正在接受二甲双胍(59%)、阿司匹林(50%)和他汀类药物(96%)治疗。36%的患者接受血管紧张素转换酶抑制剂(ACEI)治疗。在整个研究过程中,这些治疗没有变化。AGE治疗对上述代谢参数(包括胰岛素抵抗)没有显著影响。AGE治疗对内皮功能标志物(光电容积描记法)、氧化应激标志物(TAOS、GSH/GSSG、LHP)或炎症标志物(HsCRP)也没有显著影响。
在这组心血管疾病高危的2型糖尿病患者中,4周的AGE治疗并没有显著改善内皮功能、血管炎症、氧化应激或胰岛素抵抗。